Chimeric Antigen Receptor Stocks List

Recent Signals

Date Stock Signal Type
2021-04-15 ACET 20 DMA Resistance Bearish
2021-04-15 ANIX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-15 ANIX Pocket Pivot Bullish Swing Setup
2021-04-15 ANIX 20 DMA Resistance Bearish
2021-04-15 ANIX Spinning Top Other
2021-04-15 BLCM Stochastic Buy Signal Bullish
2021-04-15 CLLS 20 DMA Resistance Bearish
2021-04-15 CLLS Bollinger Band Squeeze Range Contraction
2021-04-15 CLLS Narrow Range Bar Range Contraction
2021-04-15 MBIO Bollinger Band Squeeze Range Contraction
2021-04-15 MBIO NR7 Range Contraction
2021-04-15 MBIO Narrow Range Bar Range Contraction
2021-04-15 MBIO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-15 NKTX 1,2,3 Retracement Bearish Bearish Swing Setup
2021-04-15 NKTX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-15 NKTX Pocket Pivot Bullish Swing Setup
2021-04-15 THMO NR7 Range Contraction
2021-04-15 THMO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-15 THMO Narrow Range Bar Range Contraction
2021-04-15 THMO Bollinger Band Squeeze Range Contraction

Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor.
CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors. CAR-T cells can be either derived from T cells in a patient's own blood (autologous) or derived from the T cells of another healthy donor (allogenic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.After CAR-T cells are infused into a patient, they act as a "living drug" against cancer cells. When they come in contact with their targeted antigen on a cell, CAR-T cells bind to it and become activated, then proceed to proliferate and become cytotoxic. CAR-T cells destroy cells through several mechanisms, including extensive stimulated cell proliferation, increasing the degree to which they are toxic to other living cells (cytotoxicity), and by causing the increased secretion of factors that can affect other cells such as cytokines, interleukins, and growth factors.

More about Chimeric Antigen Receptor
Browse All Tags